S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
S&P 500   0.66 (+14.63%)
DOW   0.66 (+14.63%)
QQQ   265.19 (-1.89%)
AAPL   437.50 (-2.97%)
MSFT   203.38 (-2.34%)
FB   256.13 (-2.61%)
GOOGL   1,480.54 (-1.09%)
AMZN   3,080.67 (-2.14%)
NVDA   434.00 (-2.82%)
CGC   16.95 (-5.47%)
BABA   248.42 (+0.12%)
TSLA   1,374.39 (-3.11%)
GE   6.73 (+0.90%)
MU   47.76 (-2.83%)
AMD   76.88 (-6.52%)
T   30.20 (-0.03%)
F   7.23 (+1.97%)
ACB   10.02 (-1.96%)
GILD   68.10 (-0.60%)
NFLX   466.93 (-3.40%)
DIS   130.49 (+1.32%)
BAC   26.92 (+1.36%)
BA   180.13 (+0.40%)
Log in

NASDAQ:KURAKura Oncology Stock Price, Forecast & News

$20.64
-0.65 (-3.05 %)
(As of 08/11/2020 04:00 PM ET)
Add
Compare
Today's Range
$20.54
Now: $20.64
$21.75
50-Day Range
$16.30
MA: $17.57
$21.29
52-Week Range
$6.35
Now: $20.64
$21.75
Volume550,594 shs
Average Volume527,054 shs
Market Capitalization$1.16 billion
P/E RatioN/A
Dividend YieldN/A
Beta2.24
Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer. The company's lead product candidate is Tipifarnib, an oral farnesyl transferase inhibitor that is in Phase II clinical trials for the treatment of solid tumors, peripheral T-cell lymphomas, myelodysplastic syndromes, acute myeloid leukemia, and chronic myelomonocytic leukemia. It is also developing KO-947, a small molecule inhibitor of extracellular signal related kinase used for the treatment of patients with tumors that have dysregulated activity due to mutations or other mechanisms in the mitogen-activated protein kinase pathway; and KO-539, a small molecule inhibitor of the menin-mixed lineage leukemia protein-protein interaction. The company was founded in 2014 and is headquartered in San Diego, California.
Read More
Kura Oncology logo

Beat the Market (BTM) Rank

Analyst Opinion: 2.5Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.22 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:KURA
CUSIPN/A
Phone858-500-8800

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A
Book Value$4.83 per share

Profitability

Net Income$-63,140,000.00

Miscellaneous

Employees43
Market Cap$1.16 billion
Next Earnings Date11/3/2020 (Estimated)
OptionableOptionable
$20.64
-0.65 (-3.05 %)
(As of 08/11/2020 04:00 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive KURA News and Ratings via Email

Sign-up to receive the latest news and ratings for KURA and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Kura Oncology (NASDAQ:KURA) Frequently Asked Questions

How has Kura Oncology's stock been impacted by COVID-19 (Coronavirus)?

Kura Oncology's stock was trading at $9.65 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, KURA shares have increased by 113.9% and is now trading at $20.64.
View which stocks have been most impacted by Coronavirus
.

Do Wall Street analysts recommend investors buy shares of Kura Oncology?

8 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Kura Oncology in the last year. There are currently 8 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Kura Oncology
.

When is Kura Oncology's next earnings date?

Kura Oncology is scheduled to release its next quarterly earnings announcement on Tuesday, November 3rd 2020.
View our earnings forecast for Kura Oncology
.

How were Kura Oncology's earnings last quarter?

Kura Oncology Inc (NASDAQ:KURA) issued its quarterly earnings results on Thursday, August, 6th. The company reported ($0.40) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.42) by $0.02.
View Kura Oncology's earnings history
.

What price target have analysts set for KURA?

8 Wall Street analysts have issued 1 year target prices for Kura Oncology's shares. Their forecasts range from $22.00 to $30.00. On average, they anticipate Kura Oncology's share price to reach $25.50 in the next year. This suggests a possible upside of 23.5% from the stock's current price.
View analysts' price targets for Kura Oncology
.

Has Kura Oncology been receiving favorable news coverage?

News headlines about KURA stock have trended somewhat positive recently, according to InfoTrie. The research firm scores the sentiment of news coverage by reviewing more than six thousand news and blog sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Kura Oncology earned a daily sentiment score of 1.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent news coverage is extremely unlikely to have an effect on the company's share price in the near term.
View the latest news about Kura Oncology
.

Are investors shorting Kura Oncology?

Kura Oncology saw a increase in short interest in the month of January. As of January 15th, there was short interest totaling 2,530,000 shares, an increase of 26.5% from the December 31st total of 2,000,000 shares. Based on an average daily trading volume, of 293,700 shares, the short-interest ratio is presently 8.6 days. Approximately 6.2% of the company's stock are sold short.
View Kura Oncology's Short Interest
.

Who are some of Kura Oncology's key competitors?

What other stocks do shareholders of Kura Oncology own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Kura Oncology investors own include Exelixis (EXEL), Inovio Pharmaceuticals (INO), Viking Therapeutics (VKTX), SCYNEXIS (SCYX), Amarin (AMRN), Corbus Pharmaceuticals (CRBP), VBI Vaccines (VBIV), Gilead Sciences (GILD), Aduro BioTech (ADRO) and Advanced Micro Devices (AMD).

Who are Kura Oncology's key executives?

Kura Oncology's management team includes the following people:
  • Dr. Troy Edward Wilson, Chairman, CEO & Pres (Age 50)
  • Dr. Antonio Gualberto, Head of Devel. & Chief Medical Officer (Age 54)
  • Dr. Marc Grasso, CFO & Chief Bus. Officer
  • Mr. John Farnam, Chief Operating Officer
  • Mr. Pete De Spain, VP of Investor Relations & Corp. Communications

What is Kura Oncology's stock symbol?

Kura Oncology trades on the NASDAQ under the ticker symbol "KURA."

Who are Kura Oncology's major shareholders?

Kura Oncology's stock is owned by many different retail and institutional investors. Top institutional investors include Victory Capital Management Inc. (4.47%), Candriam Luxembourg S.C.A. (0.53%), Alethea Capital Management LLC (0.38%), Swiss National Bank (0.24%), Alps Advisors Inc. (0.16%) and WINTON GROUP Ltd (0.13%). Company insiders that own Kura Oncology stock include Antonio Gualberto and Ecor1 Capital Fund Qualified,.
View institutional ownership trends for Kura Oncology
.

Which major investors are selling Kura Oncology stock?

KURA stock was sold by a variety of institutional investors in the last quarter, including Victory Capital Management Inc., Alethea Capital Management LLC, Trexquant Investment LP, Alps Advisors Inc., Virtus ETF Advisers LLC, and Exane Derivatives.
View insider buying and selling activity for Kura Oncology
.

Which major investors are buying Kura Oncology stock?

KURA stock was purchased by a variety of institutional investors in the last quarter, including Candriam Luxembourg S.C.A., Chartwell Investment Partners LLC, Swiss National Bank, SG Americas Securities LLC, New York State Common Retirement Fund, ProShare Advisors LLC, WINTON GROUP Ltd, and Rafferty Asset Management LLC.
View insider buying and selling activity for Kura Oncology
.

How do I buy shares of Kura Oncology?

Shares of KURA can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Kura Oncology's stock price today?

One share of KURA stock can currently be purchased for approximately $20.64.

How big of a company is Kura Oncology?

Kura Oncology has a market capitalization of $1.16 billion. The company earns $-63,140,000.00 in net income (profit) each year or ($1.51) on an earnings per share basis. Kura Oncology employs 43 workers across the globe.

What is Kura Oncology's official website?

The official website for Kura Oncology is www.kuraoncology.com.

How can I contact Kura Oncology?

Kura Oncology's mailing address is 3033 SCIENCE PARK ROAD SUITE 220, SAN DIEGO CA, 92121. The company can be reached via phone at 858-500-8800 or via email at [email protected]

This page was last updated on 8/11/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.